0.28
-0.0084(-2.86%)
Currency In USD
| Previous Close | 0.29 |
| Open | 0.29 |
| Day High | 0.3 |
| Day Low | 0.28 |
| 52-Week High | 1.54 |
| 52-Week Low | 0.23 |
| Volume | 454,927 |
| Average Volume | 1.2M |
| Market Cap | 22.45M |
| PE | -0.69 |
| EPS | -0.41 |
| Moving Average 50 Days | 0.37 |
| Moving Average 200 Days | 0.64 |
| Change | -0.01 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $24.49 as of February 21, 2026 at a share price of $0.285. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $21.67 as of February 21, 2026 at a share price of $0.285.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma Announces Pricing of $10 Million Public Offering
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment